Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market. The economic impact of biosimilars on the ...

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings.

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who have rheumatoid arthritis, enhancing treatment accessibility. The study, ...

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and strategic partnerships. Alvotech, an Iceland-based biosimilar-focused biotech ...

Canadian study reveals no significant differences in remission outcomes between etanercept biosimilars and the originator, Enbrel, for rheumatoid arthritis patients. As the US continues to wait for ...